To the Editor—We have read with interest by the article by Andrejko et al [1] on prediction of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following high-risk …

1 Tuite AR, Ng V, Rees E, et al. Estimation of the COVID-19 burden in Egypt through
exported case detection. Lancet Infect Dis 2020; published online March 26. https://doi …

Background The MOVe-OUT (efficacy and safety of molnupiravir [MK-4482] in non-
hospitalized adult participants with COVID-19 [MK-4482-002]) trial reported that the …

Adherence to non-pharmaceutical interventions to prevent the transmission of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has been highly variable across settings …

Objective To assess the real-world effectiveness of molnupiravir (MOL) in reducing the need
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …

The Lancet Infectious Diseases, Frank Sandmann and colleagues model a range of future
scenarios in the UK depending on vaccine efficacy, duration of protection, and use of …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which
spanned 3 years and 4 months, ended in May 2023, alongside lifting of the state of …

Cellular and humoral immunity against severe acute respiratory syndrome coronavirus
(SARS-CoV-2), either naturally acquired or vaccine-elicited, are both essential for limiting …

Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …

The coronavirus disease 2019 (COVID-19) pandemic will likely be the defining public health
event of this generation. Like no other event in recent memory, it has demonstrated the …